Literature DB >> 21571591

FKBP38-Bcl-2 interaction: a novel link to chemoresistance.

Bo-Hwa Choi1, Ho Sup Yoon.   

Abstract

FKBP38, a noncanonical member of the immunosuppressive drug FK506 binding protein (FKBP) family members, possesses an inducible rotamase. FKBP38 interacts with several proteins and regulates multiple signaling pathways such as cell survival, apoptosis, proliferation, and metastasis. Deregulation of apoptosis is associated with chemoresistance and tumor relapse. The antiapoptotic protein Bcl-2 is a key player for increasing the apoptotic threshold in response to various cytotoxic drugs. The molecular interaction of Bcl-2 with FKBP38 potentiates the biological function of Bcl-2 and contributes to tumorigenesis and chemoresistance. Here, we discuss recent advances in the role of FKBP38 in connection with Bcl-2 and its possible link to chemotherapeutic resistance.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571591     DOI: 10.1016/j.coph.2011.04.013

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  7 in total

1.  The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines.

Authors:  G Heiduschka; C Lill; S Schneider; R Seemann; G Kornek; R Schmid; U Kotowski; D Thurnher
Journal:  Strahlenther Onkol       Date:  2014-02-21       Impact factor: 3.621

Review 2.  Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.

Authors:  Andrzej Galat
Journal:  Cell Mol Life Sci       Date:  2012-12-08       Impact factor: 9.261

3.  Quantitative proteomic analysis of gene regulation by miR-34a and miR-34c.

Authors:  Olivia A Ebner; Matthias Selbach
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

4.  The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

Authors:  Angelo Gámez-Pozo; Ramón M Pérez Carrión; Luis Manso; Carmen Crespo; Cesar Mendiola; Rocío López-Vacas; Julia Berges-Soria; Isabel Álvarez López; Mireia Margeli; Juan L Bayo Calero; Xavier González Farre; Ana Santaballa; Eva M Ciruelos; Ruth Afonso; Juan Lao; Gustavo Catalán; José V Álvarez Gallego; José Miramón López; Francisco J Salvador Bofill; Manuel Ruiz Borrego; Enrique Espinosa; Juan A Fresno Vara; Pilar Zamora
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

Review 5.  Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance.

Authors:  Debashri Manna; Devanand Sarkar
Journal:  Cancers (Basel)       Date:  2021-04-09       Impact factor: 6.639

6.  Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.

Authors:  Fan Luo; Fei-Teng Lu; Miao-Zhen Qiu; Ting Zhou; Wen-Juan Ma; Min Luo; Kang-Mei Zeng; Qiu-Yun Luo; Wen-Tao Pan; Lin Zhang; Zeng-Fei Xia; Zhong-Han Zhang; Jia-Xin Cao; Hong-Yun Zhao; Li Zhang; Da-Jun Yang
Journal:  Cell Death Dis       Date:  2021-08-05       Impact factor: 9.685

7.  Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival.

Authors:  Frédérique Braun; Sophie de Carné Trécesson; Joséphine Bertin-Ciftci; Philippe Juin
Journal:  Cell Cycle       Date:  2013-08-13       Impact factor: 4.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.